Patients with anxiety or depression who engaged in health-related social media usage were significantly more likely to report to report intentions to quit smoking, endorse past 12-month attempts at smoking cessation, and were more likely to meet national recommendation for weekly strength training.
A randomized trial assessing a telehealth intervention suggest such an intervention could improve quality of life among people undergoing dialysis.
A meta-analysis of 13 trials suggests SGLT2 inhibitors reduced heart failure events and cardiovascular death across these patient populations, with consistent effects in patients with varying disease combinations.
A systematic review and meta-analysis found no significant differences in visual and anatomical outcomes between ranibizumab biosimilars and reference ranibizumab in eyes with neovascular AMD.
According to investigators, this is among the largest studies describing the risk of bacteremia in young patients with sickle cell disease.
These new findings suggest the need for expansion of JAK1/JAK2 targeting approaches for treatment of eosinophilic cellulitis and other types of eosinophilic disease.
An analysis of data from the NYC A1C Registry suggests women with gestational diabetes were more likely to develop diabetes after giving birth and were also more likely to have difficulty achieving glycemic control after diagnosis.
The results show high centrality of anxiety and depression in patients with COVID-19 and anxiety had the highest bridge influence in the network.
This new data emphasizes the vital importance of timely detection and effective treatment for squamous cell carcinomas in this particular population.
After making adjustments, the results show a positive association between alcohol dependence at 18 years and depression at age 24 years. However, there was no association between the rate of change and depression.
The rituximab biosimilar rixathon was linked to the the lowest average annual cost per patient across 6 indications among all biosimilars.
The new scientific statement from the AHA indicates multiple social, economic, and health variables contribute to disparities in the development, diagnosis, and treatment of PAD.
The FDA's historic June 20, 2023 approval of empagliflozin (Jardiance) and empagliflozin plus metformin hydrochloride (Synjardy) marks the first pediatric type 2 diabetes indication for the SGLT2 inhibitor class and comes less than a year after the debut of DINAMO data.
An analysis provided updated estimates of the US prevalence of DR and VTDR, showing that 9.6 million people had DR and 1.84 million people had VTDR in 2021.
New data led to positive results for the simple-to-use PEN-FAST tool, allowing its use among allergists and even primary care physicians in cases in which access to allergists is limited.
As frailty has a detrimental effect on outcomes in rheumatoid arthritis, it is important to be able to assess for frailty. Test your knowledge of assessing frailty in rheumatoid arthritis with this quiz.
An ENDO 2023 analysis of data suggests women with PCOS were at a 47% greater risk of mortality relative to their counterparts without the common endocrine disorder.
The new guidelines call for MDD screening for adults, including pregnant and postpartum individuals and those aged 65 years and older, which would have a moderate net benefit.
This new tool, using an automated analysis of different parts of the body, could help clinicians to address previously unmet needs for treatment in conditions such as psoriasis.
Announced by AGEPHA Pharma US on June 20, 2023, the US FDA approval of colchicine 0.5 mg tablets (Lodoco) for reducing cardiovascular event risk marks the first approval in agency history for an anti-inflammatory atheroprotective cardiovascular treatment.
NLR values were similar between significant and minimal fibrosis and were not correlated with significant fibrosis.
Data from the open-label extension portion of the phase 3 PaTHway trial detail the long-term effects of TransCon PTH use among people with chronic hypoparathyroidism.
Among other associations, those in educational attainment, employment status, mental health, and pain episode frequency and severity highlight the need for comprehensive care that considers the psychological well-being of individuals with SCD.
The analysis of the DRCR Retina Network Protocol AC suggested cost savings occur with bevacizumab-first step therapy in eyes with DME, but the magnitude might not be as great as previously understood.
Investigators explain understanding these disparities is crucial for developing targeted interventions to improve screening rates and reduce health inequities.
These new guidelines were developed to benefit younger patients with inflammatory skin diseases, and may be helpful given the inexpensive nature and general availability of the drug.
Combination methotrexate plus bDMARDs, bsDMARDs, and tsDMARDs provided .009 to .33 quality-adjusted life years gained with additional costs of $15,957 to $60,722 when compared with standard of care.
Additional phase 4 trial results presented at ENDO 2023 reinforce the efficacy and safety of teprotumumab-trbw in eyes with TED, regardless of disease activity or duration.
Patients with anti-HDV antibodies had a significantly higher prevalence of liver cirrhosis, significantly lower prothrombin time, and a higher prevalence of HIV co-infection compared to patients who demonstrated serum anti-HDV antibody negatively.
This cardiology case report from Brady Pregerson, MD, features man in his late-60s presenting to urgent care with 3 days of upper respiratory infection symptoms and one episode of near syncope. Check out the ECG and see if you can determine the correct diagnosis!
